seems that there was some news this morning. can't really tell if it is good or bad, but appears to be good by market action. hope this helps
Company Press Release
SOURCE: Cephalon, Inc.
Cephalon Announces Senior Management Appointments
WEST CHESTER, Pa., Dec. 1 /PRNewswire/ -- Cephalon, Inc. (Nasdaq: CEPH - news) announced today the appointments of Jeffry Vaught, Ph.D., to the position of president, research and development division, Peter Grebow, Ph.D., to senior vice president, worldwide business development and Efraim Shek, Ph.D., to vice president, drug development.
In his new position, Dr. Vaught will oversee all of the company's discovery research and drug development activities and operations, and will continue to report to Frank Baldino, Jr., Ph.D., Cephalon's president and CEO. Dr. Vaught joined Cephalon in 1991 as vice president of research after nine years at Johnson and Johnson in CNS research positions of increasing responsibility, and was promoted to senior vice president of research in 1994.
Dr. Grebow will be responsible for licensing technology and compounds for clinical development and for developing and maintaining corporate research and development collaborations. He joined Cephalon in 1991 as director of drug development, and became senior vice president of drug development in 1994. Previously, Dr. Grebow spent fifteen years at Rhone-Poulenc Rorer in drug development. He will continue to report to Dr. Baldino.
Dr. Shek joined Cephalon in 1994 as vice president, pharmaceutics and analytical chemistry. Previously, he spent seventeen years at Syntex in drug development positions of increasing responsibility. In his new position as vice president, drug development, he will oversee the company's drug safety and disposition activities and chemical, pharmaceutical and analytical development operations, reporting to Dr. Vaught.
''Jeff, Peter and Efraim are valuable members of Cephalon's management team,'' said Dr. Baldino. ''Their considerable scientific talents and years of pharmaceutical research and development experience will help Cephalon continue to develop and commercialize innovative products to treat neurological disorders. We believe these appointments will enhance the company's ability to maximize its opportunities for success.''
Cephalon, Inc., headquartered in West Chester, PA, is an international biopharmaceutical company that discovers, develops and markets products to treat neurological disorders. The company is developing products for the treatment of ALS, narcolepsy, peripheral neuropathies, Alzheimer's disease and stroke, and currently copromotes three products in the United States for the treatment of neurological conditions.
This news release may contain forward-looking statements that involve risks and uncertainties. A full discussion of Cephalon's operations and financial condition, including factors that may affect the company's business and future prospects, is contained in documents the company files with the SEC, such as form 10-Q and 10-K reports. These documents identify important factors that could cause the company's actual performance to differ from current expectations.
NOTE: Cephalon's press releases are available by fax 24 hours a day at no charge by calling PR Newswire's Company News On-Call at 800-758-5804, extension 134563. They are also posted on the Internet at prnewswire.com.
SOURCE: Cephalon, In |
